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Although the antimicrobial activity of lactoferrin has been well described, its mechanism of action has been
poorly characterized. Recent work has indicated that in addition to binding iron, human lactoferrin damages the
outer membrane of gram-negative bacteria. In this study, we determined whether bovine lactoferrin and a
pepsin-derived bovine lactoferrin peptide (lactoferricin) fragment have similar activities. We found that both 20
,uM bovine lactoferrin and 20 FM lactoferricin release intrinsicaly labeled [3HJlipopolysaccharide ([3H]LPS)
from three bacterial strains, Escherichia coli CL9 1-2, SalnoneUa typhimurium SL696, and SalmonelUa
montevideo SL5222. Under most conditions, more LPS is released by the peptide fragment than by whole bovine
lactoferrin. In the presence of either lactoferrin or lactoferricin there is increased killing ofE. coli CL9 1-2 by
lysozyme. Like human lactoferrin, bovine lactoferrin and lactoferricin have the ability to bind to free intrinsically
labeled [3H]LPS molecules. In addition to these effects, whereas bovine lactoferrin was at most bacteriostatic,
lactoferricin demonstrated consistent bactericidal activity against gram-negative bacteria. This bactericidal effect
is modulated by the cations Ca2+, Mg2+, and Fe3+ but is independent of the osmolarity of the medium.
Transmission electron microscopy of bacterial cells exposed to lactoferricin show the immediate development of
electron-dense "membrane blisters." These experiments offer evidence that bovine lactoferrin and lactoferricin
damage the outer membrane of gram-negative bacteria. Moreover, the peptide fragment lactoferricin has direct
bactericidal activity. As lactoferrin is exposed to proteolytic factors in vivo which could cleave the lactoferricin
fragment, the effects of this peptide are of both mechanistic and physiologic relevance.
Lactoferrin is an iron-binding glycoprotein present in
milk, tears, saliva, vaginal secretions, semen, bronchoalve-
olar lavage fluid, and specific granules of polymorphonuclear
leukocytes (PMNs) (10, 13, 39). Biological properties as-
cribed to this protein include the regulation of absorption of
iron and other metals in the gastrointestinal tract, modula-
tion of both the production of PMNs and the growth of
animal cells, and finally antimicrobial activity against bacte-
ria and yeasts (34, 40, 45). Initially, the antimicrobial effect
of lactoferrin was considered to be a function of its ability to
chelate iron, with the protein inhibiting microbial growth
through nutritional deprivation of iron (21). However, sev-
eral investigators have suggested that lactoferrin has other
effects against microorganisms. Work by Arnold and asso-
ciates (2, 3, 7, 8, 30) has suggested that lactoferrin is capable
of a direct bacterial effect on strains of Streptococcus
mutans, Vibrio cholerae, Escherichia coli, Actinobacillus
actinomycetemcomitans, and Legionella pneumophila. Ad-
ditionally, several research groups have found that the
antimicrobial activity of lactoferrin against E. coli strains is
enhanced by concurrent exposure of the bacteria to immu-
noglobulin G or secretory immunoglobulin A (44, 48, 49).
More recently, we have found that human lactoferrin can
directly damage the outer membrane of gram-negative bac-
teria (16-19). Lactoferrin causes the release of lipopolysac-
charide (LPS) molecules from the membrane and enhances
bacterial susceptibility to hydrophobic antibiotics and hu-
man lysozyme. These effects on the outer membrane of
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Massachusetts Medical Center, 55 Lake Avenue North, Worcester,
MA 01655.
gram-negative bacteria appear to be related to a direct
interaction of lactoferrin with the bacterial cell (16).
Work with bovine lactoferrin has found that the antimi-
crobial activity of an enzymatic hydrolysate generated by
digestion with porcine pepsin is stronger than that of the
whole protein against an E. coli 0111 isolate (51). The
bacteriostatic activity is associated with low-molecular-
weight peptide fragments, and an active lactoferrin peptide
fragment has been purified by reverse-phase high perfor-
mance liquid chromatography (5). Sequence analysis indi-
cates that this peptide fragment is 25 amino acids long
(Phe-Lys-Cys-Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Leu-
Gly-Ala-Pro-Ser-Ile-Thr-Cys-Val-Arg-Arg-Ala-Phe) and has
exact homology with an amino-terminal segment of the
whole lactoferrin sequence, as reported by Pierce et al. (43)
and by Goodman and Schanbacher (26). The segment of the
N terminus involved is distinctly separate from the two
iron-binding regions of the protein. It contains five arginine
and three lysine residues, making it strongly cationic, and
lacks detectable carbohydrate. A search of the NBRF-PIR
databank found that it has strong homology with an N-ter-
minal region of mouse lactoferrin, but not with other cationic
antimicrobial proteins. In this report, we have investigated
the effects of both whole bovine lactoferrin and its peptide
fragment, lactoferricin, on the gram-negative bacterial outer
membrane and have further characterized the antimicrobial
activity of lactoferricin.
MATERIALS AND METHODS
Lactoferrin and lactoferricin. Bovine milk lactoferrin was
prepared from fresh skim milk by the method described by
Law and Reiter (32), and purity was ascertained by sodium
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dodecyl sulfate-polyacrylamide gel electrophoresis (51). The
bovine lactoferrin peptide lactoferricin was prepared by the
method of Bellamy et al. (5). Human milk lactoferrin (Sigma
Chemical Company [St. Louis, Mo.] or Calbiochem Corpo-
ration [La Jolla, Calif.]) and human placental lysozyme
(Calbiochem) were purchased commercially.
LPS release studies. The abilities of bovine lactoferrin and
lactoferricin to release LPS was tested by previously de-
scribed methods with three different bacterial strains (E. coli
CL99 1-2, Salmonella montevideo SL5222, and Salmonella
typhimurium SL696) (16, 18). Briefly, the LPS of each of
these bacteria was intrinsically radiolabeled through the
incorporation of tritiated galactose into the carbohydrate
component of the LPS molecule (6, 17, 18, 25, 28, 29, 56).
The strain to be tested was grown at 37°C in 1 ml of defined
medium (WMS broth, Davis minimal medium, Luria broth,
or Luria broth with calcium [16, 18]) supplemented with 0.1
mM unlabeled galactose and 4 to 15 ,uCi of D-[6-3H]galactose
to reach a concentration of =5 x 108 CFU. The cells were
then centrifuged, washed, and suspended in Hanks' bal-
anced salt solution lacking calcium and magnesium (HBSS-
CM) (Sigma). Duplicate 1.0-ml samples containing approxi-
mately 5 x 107 CFU of [3H]galactose-labeled bacteria,
buffer, and various concentrations of test materials in poly-
propylene tubes at pH 7 to 7.5 were prepared. After the
addition of bacteria, 0-min samples were immediately agi-
tated and centrifuged, and the beta emissions from the
supernatant and pellet fractions were counted. The 30-min
samples were incubated at 37°C and then similarly agitated,
centrifuged, and counted.
The percentage of radiolabel released at 30 min was
determined as follows: percent release = [30-min sample
supernatant cpm/(30-min sample supernatant cpm + 30-min
sample pellet cpm)] x 100 - [0-min buffer supernatant
cpm/(0-min buffer supernatant cpm + 0-min buffer pellet
cpm)] x 100, where cpm is the counts per minute.
Time-kill studies. Bacto Peptone medium was obtained
commercially (Difco, Detroit, Mich.), and 1% (wt/vol) solu-
tions were prepared. E. coli CL99 1-2 cells were grown to
stationary phase, centrifuged, and washed. A bacterial inoc-
ulum was added to 500 ,ul of medium (Bacto Peptone) with or
without lactoferricin, bovine lactoferrin, human lactoferrin,
or human lysozyme. The mixtures were then incubated at
37°C, and aliquots were removed, serially diluted, and plated
on tryptic soy agar (BBL) to determine bacterial colony
counts. For data analysis, if no viable bacteria were ob-
served at the lowest dilution, the bacterial count was re-
corded as 1 CFU at that dilution. For example, if the lowest
dilution without bacterial growth for a given experiment was
1:102, the bacterial CFU was considered to be 102.
LPS binding studies. We studied the ability of the proteins
to bind LPS using our previously described assay (16).
Bovine lactoferrin, lactoferricin, bovine serum albumin
(BSA) and poly-L-lysine (Sigma Chemical Co.) were coupled
to cyanogen bromide-activated Sepharose 4B beads (Phar-
macia Fine Chemicals) at a concentration of 100 nM/ml of
gel. After protein coupling, the beads were blocked in Tris
buffer (pH 8.0) and stored in 0.03 M barbital-acetate-0.116 M
NaCl buffer (pH 7.2) (BABS) with 0.02% thimerosal. To
control for nonspecific binding, Sepharose beads that were
not reacted with protein but instead simply blocked with Tris
were also prepared.
Tritium-labeled LPS was prepared by growing E. coli
CL99 1-2 in modified WMS broth supplemented with D-
[6-3H]galactose, and LPS was extracted either by washing
the cells in barbital-acetate buffer (pH 8.0) or by the phenol-
water method of Westphal and Jann (17, 55). When this
strain is grown in the presence of [3H]galactose, the radio-
label is almost exclusively incorporated into the 0-specific
side chain of LPS (25). For experiments requiring high LPS
concentrations, [3H]LPS was supplemented with similarly
prepared unlabeled LPS.
Binding of the LPS was determined by incubating 0.1-ml
portions of the protein-Sepharose or Tris-Sepharose beads
with various concentrations of [3H]LPS in BABS (pH 7.2)
for 1 h with occasional gentle shaking. The beads were then
pelleted by centrifugation, washed twice with BABS, and
the beads and pooled BABS wash material was subjected to
liquid scintillation counting.
MIC and MBC tests. Determination of the MIC and MBC
of lactoferricin for bacterial strains was performed in 1%
Bacto Peptone medium, using a standard microdilution
technique with an inoculum of 2 x 105 CFU/ml (23).
TEM. Inocula (5 x 107 CFU) of E. coli CL99 1-2 were
added to 1-ml portions of 1% Bacto Peptone with or without
100 ,ug of lactoferricin. The mixtures were incubated at 37°C
for various time periods, and the bacterial cells were pel-
leted. The pellets were resuspended in 2% glutaraldehyde in
0.1 M cacodylic buffer (pH 7.3) for 30 min at 4°C and washed
twice in 0.1 M cacodylic buffer. The samples were postfixed
in buffered 1% osmium tetroxide, dehydrated through a
graded series of ethanols, and embedded in Poly/bed 812-
araldite (Mollenhauer medium; Polysciences, Inc., War-
rington, Pa.). For transmission electron microscopy (TEM),
thin sections (70 nm thick) were obtained with diamond
knives and stained routinely with aqueous solutions of
uranyl acetate and lead citrate. Sections were examined with
a Philips CM-12 transmission electron microscope at 60 kV.
RESULTS
LPS release studies. To study the effects of bovine lactofer-
rin and lactoferricin on the outer membrane, we determined
whether they could release LPS from three bacterial strains,
E. coli CL99 1-2, S. typhimurium SL696, and S. montevideo
SL5222. In initial studies performed with bacterial cells
grown with 2mM calcium, we found that 18 ,uM lactoferricin
caused a dramatic release of 3H-labeled LPS from all three
bacterial strains (Table 1). In comparison, the approximately
the same molar concentration of whole bovine lactoferrin
protein caused a lower degree of LPS release from the two
Salmonella strains. These results are comparable to those
from a previous study with human lactoferrin (18) and
suggest that both bovine lactoferrin and lactoferricin, the
peptide with N-terminal region, can damage the gram-nega-
tive bacterial outer membrane.
Prior work has indicated that growing bacterial cells in the
presence of increasing concentrations of calcium ions in-
creased the percentage of LPS that could be released by
EDTA and human lactoferrin (16). Presumably, when the
outer membrane is assembled in the presence of high con-
centrations of cations, increased numbers of cations are
incorporated into the membrane to stabilize the anionic
charge of the LPS core. The increased amount of cations
within the membrane may then make the membrane more
susceptible to factors that alter the cation-LPS relationship.
Using this hypothesis, we similarly studied the effect of
calcium in growth medium on the ability of bovine lactofer-
rin and lactoferricin to release LPS from S. typhimurium
SL696 (Table 1). As previously noted with human lactofer-
rin, the amount of LPS released from the bacterial mem-
brane by bovine lactoferrin significantly increased as the
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LACTOFERRIN AND LACTOFERRICIN 721
TABLE 1. Release of LPS from three bacterial strains by bovine lactoferrin and lactoferricin
% [3H]LPS release (mean ± SEM) (n) at 30 min with HBSS-CM
Bacteria and growth medium With bovine lactoferrin With lactoferricinAlone (2 mg/ml) (100 Rg/ml)
E. coli CL99 1-2, WMS broth 1.1 ± 1.1 (3) 0.8 ± 0.8 (3) 26.6 ± 3.4a (3)
S. montevideo SL5222, Luria broth + 2 mM calcium 3.4 ± 1.9 (3) 24.6 ± 2.0b (3) 39.8 ± 10.6b (2)
S. typhimurium SL696
Luria broth 4.5 ± 2.6 (5) 1.5 ± 0.7 (5) 49.5 ± 2.1c (5)
Luria broth + 2 mM calcium 4.6 ± 1.0 (7) 22.8 ± 6.8d (5) 45.5 ± 1.8e (7)
Luria broth + 10 mM calcium 4.9 ± 1.1 (5) 58.0 ± 6.7fg (5) 47.4 + O.7f (5)
a Significantly different from value obtained with HBSS-CM and bovine lactoferrin (P < 0.05).b Significantly different from value obtained with HBSS-CM alone (P < 0.05).
c Significantly different from value obtained with HBSS-CM and bovine lactoferrin (P < 0.0001).
d Significantly different from value obtained with HBSS-CM (P < 0.005).
e Significantly different from value obtained with HBSS-CM and bovine lactoferrin (P < 0.05).
f Significantly different from value obtained with HBSS-CM (P < 0.0001).
g Significantly different from value obtained with Luria broth and no supplemental calcium (P < 0.01).
concentration of calcium ions in the growth medium in-
creased. In contrast, the ability of lactoferricin to release
LPS appeared to be independent of the calcium concentra-
tion of the growth medium.
With the high degree of radiolabel being released, concur-
rent experiments were performed to test the effect of bovine
lactoferrin and lactoferricin on bacterial viability under these
experimental conditions. Although lactoferrin had no effect,
lactoferricin caused a greater than 99% decrease in bacterial
CFU in HBSS-CM during the 30-min incubation for each of
the Salmonella strains.
Bacterial susceptibility to human lysozyme. To determine
whether the ability of bovine lactoferrin and lactoferricin to
release LPS from the bacterial cell also altered the perme-
ability of the outer membrane, we studied the effects of the
proteins on bacterial susceptibility to human lysozyme. As
previously observed with human lactoferrin, we found that
there was increased killing of E. coli CL99 1-2 in 1% Bacto
Peptone medium containing bovine lactoferrin and human
lysozyme (Fig. 1). Similarly, there was also increased killing
of bacterial cells that were concurrently exposed to lacto-
ferricin and lysozyme as opposed to either of these com-
pounds alone (Fig. 2). This interaction was dependent on the
concentration of lactoferricin, with increasing bacterial kill-
ing seen as lactoferricin concentration was increased from 2
to 8 ,ug/ml (data not shown).
LPS binding studies. Human lactoferrin and polycationic
agents not only alter bacterial outer membrane permeability
but also directly bind LPS (16, 38). We attempted to ascer-
tain whether bovine lactoferrin and lactoferricin also have
this property. In studies with intrinsically radiolabeled LPS,
we found that bovine lactoferrin and lactoferricin have
similar abilities to bind LPS, and each has a stronger ability
to bind LPS than do BSA and poly-L-lysine (Fig. 3). An
exact calculation of the number of LPS binding sites and the
Kd for the interactions with lactoferrin or lactoferricin is not
possible both because of the inability to define the molar
concentration of LPS (because of size variability) and be-
cause of the capacity for free LPS molecules to aggregate in
solution.
Bactericidal activity of lactoferricin. As the experiments
above indicated that lactoferricin has bactericidal activity in
addition to an effect on the gram-negative bacterial outer
membrane, further time-kill studies were performed. In
experiments with E. coli CL99 1-2 in 1% Bacto Peptone
medium, we found that lactoferricin exhibited a consistent
bactericidal effect (Fig. 4). The activity was proportional to
the concentration of lactoferricin and inversely proportional
to the bacterial inoculum. Specifically, lactoferricin at a
concentration of 100 ,ug/ml was highly bactericidal, regard-
less of the inoculum size. Over a 1-h incubation, there was a
greater than 99% reduction in CFU, and subsequent bacte-
rial killing continued through 24-h incubation. A lactoferricin
concentration of 10 ,ug/ml was also bactericidal, but the
activity of this lower lactoferricin concentration was inocu-
lum dependent. The lactoferricin concentration of 1.0 ,ug/ml
had no apparent effect on the bacterial cells.
As these studies had been performed with stationary-
phase organisms, time-kill curves were also performed with
lactoferricin against log-phase bacteria for which a greater
bactericidal effect was observed (data not shown). Addition-
ally, because prior work found that a bactericidal effect of
lactoferrin against L. pneumophila was seen against broth-
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FIG. 1. Effects of human lysozyme (12.5 ,ug/ml) and human
lactoferrin (2 mg/ml) and bovine lactoferrin (2 mg/ml) on the growth
of E. coli CL99 1-2 in 1% Bacto Peptone alone or supplemented.
Each value shown is the mean + standard error of the mean from
three experiments. Symbols: 0, no supplement; 0, human lacto-
ferrin; >, bovine lactoferrin; *, human lysozyme; *, human
lactoferrin and human lysozyme; Pi, bovine lactoferrin and human
lysozyme.
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FIG. 2. Effects of human lysozyme (6 ,ug/ml) and lactoferricin (8
p,g/ml) on the growth of E. coli CL99 1-2 in 1% Bacto Peptone alone
or supplemented. Each value shown is the mean ± standard error of
the mean from three to five experiments. Symbols: 0, no supple-
ment; El, lactoferricin; 0, human lysozyme; lactoferricin and
human lysozyme.
grown but not agar-grown cells, we tested the activity of
lactoferricin against E. coli 0111 grown on agar plates (7). In
parallel experiments, lactoferricin at a concentration of 100
,ug/ml was bactericidal for cells grown under both condi-
tions, but the magnitude of bacterial killing at 24 h was lower
for agar-grown cells (decrease in CFU of 3.13 log1o units
[mean of three experiments]) than for broth-grown cells (4.69
log1o units).
There appeared to be some bacterial growth at 24 h when
high bacterial inocula were exposed to 10 ,ug of lactoferricin
30000
25000
v 20000
z
15000
0
m
-10000
5000
0 10000 20000 30000 40000
TOTAL LPS LOADED (ng)
FIG. 3. Binding of E. coli CL99 1-2 [3H]LPS to bovine lactofer-
rin (C1), lactoferricin (A), poly-L-lysine (O), and BSA (V) bound to
Sepharose and to Tris-blocked Sepharose (0). Each value shown is
the mean ± standard error of the mean from three experiments. The
binding curves are plotted, using second-order linear regression.
per ml, suggesting that the strain might develop one-step
resistance to lactoferricin, as can be seen with selected
antibiotics such as rifampin. To test the possibility that such
resistance to lactoferricin could occur, bacterial cells surviv-
ing 24 h of exposure to 10 ,ug of lactoferricin per ml at an
inoculum size of 107 CFU/ml were reexposed to the same
lactoferricin concentration in a 105 CFU inoculum (Fig. 5). A
rapid bactericidal effect for lactoferricin was again observed.
These results suggest that the observed variation in activity
with inoculum size is not due to the rapid emergence of
resistant organisms but instead relates to the ratio of lacto-
ferricin molecules to bacterial cells.
Our prior work with human lactoferrin indicated that
lactoferrin and lysozyme could kill gram-negative organisms
only under low osmotic conditions (16). To evaluate whether
the in vitro killing by lactoferricin was similarly related to the
osmolarity of the medium, we tested the activity of the
peptide in Bacto Peptone medium supplemented with myo-
inositol, a sugar not metabolized by E. coli CL99 1-2. We
found that increasing the osmolarity of the medium up to 288
mosM had no impact on the bactericidal effect (Fig. 6).
The segment of the bovine lactoferrin N-terminus-contain-
ing lactoferricin is distinct from the two iron-binding re-
gions of the protein, which suggests that iron would not
influence its activity. In testing this hypothesis, we found
that 80 ,uM ferric chloride had no effect on the activity of 18
,uM lactoferricin, although it did inhibit the effect of 2 ,uM
lactoferricin, particularly after incubation for 24 h (Fig. 7). In
contrast, 80 uLM ferric chloride completely inhibited the
activity of 20 ,uM bovine lactoferrin. The fact that the
inhibition of lactoferricin occurred at a higher iron-to-protein
ratio than the inhibition of lactoferrin suggests that the effect
of ferric iron on the activity of lactoferricin is due to a
different mechanism than that for bovine lactoferrin.
Similarly, it has been noted that calcium and magnesium
can affect the antimicrobial activities of human lactoferrin
and several neutrophil-derived cationic proteins, including
the bactericidal/permeability-increasing protein (BPI), the
defensins, and the bactenecins (18, 35, 47, 52). Thus, we
tested the effects of increasing calcium and magnesium
levels on the antimicrobial activity of lactoferricin (Fig. 8).
We found that both cations could inhibit the activity of
lactoferricin against E. coli CL99 1-2, but the peptide re-
tained a demonstrable effect at calcium and magnesium
concentrations of 100 ,M.
MIC and MBC studies. To further evaluate the spectrum of
antimicrobial activity of lactoferricin, we determined the
MICs and MBCs of the peptide against a variety of micro-
organisms in 1% Bacto Peptone medium (Table 2). With 10
Gram-negative strains, the MICs ranged from 1.6 to 5.2
,ug/ml. For isolates of the family Enterobacteriaceae, the
MBCs were almost identical to the MICs. In contrast, for
two Pseudomonas aeruginosa isolates, the peptide had only
an inhibitory effect, with the MBC greater than 125 p,g/ml.
For three gram-positive strains and two Candida albicans
isolates, the MICs and MBCs of lactoferricin were very
close and ranged from 0.8 to 13.2 ,ug/ml.
TEM studies. To further characterize the bactericidal effect
of lactoferricin, we used TEM to examine E. coli CL99 1-2
cells treated with lactoferricin (Fig. 9). We found that bacte-
rial cells exposed to 100 ,ug of lactoferricin per ml immediately
showed an altered cell membrane morphology, with the
appearance of membrane "blisters." After 2 h of incubation
with 100 ,ug of lactoferricin per ml, a large amount of cell
debris was present, and a number of the remaining cells
appear to have a clumping or coagulation of cytoplasmic
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Inoculum size: 5x105 CFU/ml
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FIG. 4. Effects of the size of bacterial inoculum and the concentration of lactoferricin on the activity of lactoferricin toward E. coli CL99
1-2 in 1% Bacto Peptone. Symbols: 0, no lactoferricin; El, 1.0 ,ug of lactoferricin per ml; >, 10 ,ug of lactoferricin per ml; K, 100 ,ug of
lactoferricin per ml. SEM, standard error of the mean; EXP, experiments.
elements, in addition to membrane blistering. These effects
are distinctly different from those noted with whole human
lactoferrin which has no effect on bacterial morphology by
TEM (16).
DISCUSSION
In this work, we have found that bovine lactoferrin alters
the structure of the gram-negative bacterial outer membrane.
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FIG. 5. Evaluation of the bactericidal activity of lactoferricin
toward E. coli CL99 1-2 cells which survive in the medium (Bacto
Peptone) containing lactoferricin. Each value shown is the mean
standard error of the mean from two or three experiments. Symbols:
O and 0, no lactoferricin; El and *, 10 ,ug of lactoferricin per ml; 0
and El, cells which had grown in 1% Bacto Peptone for 24 h; 0 and
*, cells which had been inoculated at 107 CFU/ml and had survived
24 h in 1% Bacto Peptone containing 10 p,g of lactoferricin per ml.
The protein causes both the release of structural LPS
molecules and an increase in killing of bacteria by human
lysozyme. In this fashion, it appears to have an effect similar
to that of human lactoferrin (16-19). Experiments with
human lactoferrin had indicated that its membrane activity
was related to an ability to directly interact with the mem-
brane and that the protein binds LPS molecules (16). We
have now found that the bovine protein shares this latter
property.
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FIG. 6. Evaluation of the bactericidal activity of lactoferricin (10
pLg/ml) toward E. coli CL99 1-2 in 1% Bacto Peptone medium alone
or supplemented with myo-inositol and with increasing osmolarities.
Each value shown is the mean + standard error of the mean from
three experiments. Symbols: 0, no inositol or lactoferricin, 54
mosM; E, 100 mM inositol, 148 mosM; >, 250 mM inositol, 288
mosM; 0, lactoferricin, 54 mosM; U, lactoferricin, 148 mosM; *,
lactoferricin, 288 mosM.
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FIG. 7. Evaluation of the bactericidal activity of bovine lacto-
ferrin and lactoferricin toward E. coli CL99 1-2 in 1% Bacto Peptone
alone or supplemented with ferric chloride. Lactoferrin and lacto-
ferricin were incubated in medium with iron for 1 h at 37°C prior to
the addition of bacteria. Each value shown is the mean ± standard
error of the mean from two or three experiments. Symbols- 0, no
supplement; El, 2 mg of bovine lactoferrin per ml; >, 10 ,ug of
lactoferricin per ml; O, 100 ,ug of lactoferricin per ml; 0, 80 p,M
Fe3"; E, 2 mg of bovine lactoferrin per ml and 80 ,uM Fe3+; *, 10
pg of lactoferricin per ml and 80 p,M Fe3+; *, 100 ,ug of lactoferricin
per ml and 80 p,M Fe3+
The concentration of lactoferrin required to alter the outer
membrane is high, indicating that this activity will not occur
in all physiologic environments. However, lactoferrin has
been found at the following levels in body fluids: 0.5 ± 0.5
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FIG. 8. Evaluation of the bactericidal activity of lactoferricin
(100 ,ug/ml) toward E. coli CL99 1-2 in HBSS-CM alone or supple-
mented with increasing calcium (A) and magnesium (B) concentra-
tions. Each value shown is the mean + standard error of the mean
from three experiments. (A) Symbols: 0, no supplement; *, lacto-
ferricin; U, lactoferricin and 100 ,uM CaC12; 4, lactoferricin and 200
F.M CaCl2; *, lactoferricin and 1 mM CaCl2; (B) Symbols: 0, no
supplement; 0, lactoferricin; *, lactoferricin and 100 p.M MgCI2; 4,
lactoferricin and 200 F.M MgCl2; *, lactoferricin and 1 mM MgCl2.
TABLE 2. Antimicrobial activity of bovine lactoferricin against
selected bacteria and yeast strains in Bacto Peptone
Bacterial strain or isolatea mic) MBCi(FLaml) (ILgml)
E. coli CL99 1-2
Prepn 1 4 8
Prepn 2 13 17
S. typhimurium SL696
Prepn 1 5 8
Prepn 2 21 21
S. montevideo SL5222
Prepn 1 3 9
Prepn 2 13 13
S. typhimurium 6749 1.6 3.3
S. typhimurium SH7641 1.6 1.6
E. coli K-12 UB1005 1.6 1.6
E. coli K-12 UB1005 DC-2 1.6 1.6
E. coli ATCC 25922 3.3 3.3
P. aeruginosa ATCC 2783 3.3 >125
P. aeruginosa PAO-1 3.3 >125
Staphylococcus aureus ATCC 29213 6.6 13.2
L. monocytogenes EGD 1.6 3.3
L. monocytogenes 4b (maritime) 6.6 13.2
C. albicans 6372 0.8 0.8
C. albicans 6434 0.8 0.8
a E. coli CL99 1-2, S. typhimurium SL696, and S. montevideo SL5222 were
tested against two separate preparations of lactoferricin purified by two
different high-performance liquid chromatographic schema. All other isolates
were tested against a single lactoferricin preparation. E. coli UB1005 and
UB1005 DC-2 are a laboratory parental strain and a polymyxin B-hypersus-
ceptible mutant (45a). P. aeruginosa PAO-1 and L. monocytogenes EGD are
defined laboratory isolates. L. monocytogenes 4b (maritime) is a clinical
epidemic strain, and the C. albicans strains are blood culture isolates from the
University of Colorado Health Sciences Center Clinical Microbiology Labo-
ratory.
b Values shown are the means from two to six experiments.
mg/ml (mean ± standard deviation) in pooled pulmonary
secretions; above 6 mg/ml in preterm colostrum; and above
14 mg/ml in infected parotid fluid (9, 41, 50). Additionally,
lactoferrin is released from PMNs in response to cytokine
stimulation and in response to gram-negative bacterial infec-
tion. As the levels of lactoferrin in plasma during acute
sepsis can reach 0.2 mg/ml, it is likely that local concentra-
tions at sites of inflammation will be in the range of milli-
grams per milliliter (27, 31). Thus, lactoferrin levels similar
to those studied may be found in sites of bacterial infection,
as well as within the neutrophil phagolysosome and within
colostral milk.
In addition to this activity of whole bovine lactoferrin, we
have found that the peptide fragment of the protein, lacto-
ferricin, has very comparable effects on the outer mem-
brane. These observations suggest that at a minimum the
amino-terminal domain of the whole protein comprising
lactoferricin makes a major contribution to the outer mem-
brane activity of lactoferrin. It is conceivable that this
domain is the sole site in lactoferrin contributing to the
membrane effects. This hypothesis is consistent with recent
X-ray crystallographic observations with human lactoferrin
(1). Crystallographic analysis indicates that the region of
human lactoferrin approximating the lactoferricin segment of
bovine lactoferrin is surface exposed, and thus in a location
where it could interact with either free LPS or a bacterial
cell.
However, in addition to its outer membrane effects, lact-
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cFIG. 9. TEM of E. coli CL99 1-2 cells. The cells were incubated for 2 h in 1% Bacto Peptone alone (A), incubated for 0 h in 1% Bacto
Peptone with 100 ,ug of lactoferricin per ml (B), and incubated for 2 h in 1% Bacto Peptone with 100 p.g of lactoferricin per ml (C). Bars,
500 nm.
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oferricin can also be directly microbicidal for a variety of
gram-negative and -positive bacteria, as well as C. albicans.
For gram-negative bacteria, the activity of lactoferricin is
dose dependent, inversely proportional to the bacterial in-
oculum, and modulated by cations Ca2+, Mg2+, and Fe3+.
TEM analysis found that lactoferricin dramatically alters the
morphology of both the bacterial cell membrane and cyto-
plasm.
In all these properties, the peptide lactoferricin shows
marked similarities to a variety of PMN proteins including
BPI, defensins, and bactenecins (22, 24, 33, 37, 47, 53, 54).
Although the amino acid sequence of lactoferricin is unique,
like these other proteins, it is highly cationic and alters outer
membrane permeability (33, 47, 53, 54). With BPI, it shares
an ability to bind LPS (38), and with the defensins, it shares
an ability to kill gram-negative bacteria and C. albicans (22,
35). Additionally, both BPI and the defensins produce alter-
ations in the gram-negative bacterial outer membrane mor-
phology observable by TEM, although neither produce the
blister-like effects of lactoferricin (33, 52).
It is important to consider that lactoferricin is released
from whole bovine lactoferrin after hydrolysis with pepsin
(5), which raises the possibility that the peptide fragment is
released from orally ingested lactoferrin in vivo. Moreover,
in that an aspartic protease of Penicillium duponti also
appears to release the peptide from lactoferrin (51), it is
possible that lactoferricin will also be freed from lactoferrin
in vivo under other conditions when the whole protein is
exposed to proteases. One important environment in which
this could occur is the phagolysosome of PMNs and macro-
phages, where a variety of proteases is present (20). Al-
though lactoferrin is not produced by macrophages, recent
work suggests that the protein can be found within these
cells in vivo and contribute to their antimicrobial activity
against L. pneumophila, Mycobactenium microti, and
Trypanosoma cruzi (11, 36, 46).
There are high concentrations of calcium and magnesium
in most biological fluids that could limit the activity of
lactoferrin and lactoferricin. However, the in vivo distribu-
tion of the cations is not homogeneous. Work by Pollack and
associates indicates that the phagolysosome of macrophages
has a calcium concentration of less than 100 ,uM, an envi-
ronment where lactoferrin should have activity against the
gram-negative bacterial outer membrane and lactoferricin
would be bactericidal. Additionally, as noted above, the
membrane effects of lactoferrin and lactoferricin appear
dependent on a mechanism of action similar to that of the
neutrophilic cationic antimicrobial proteins. Both Ca2` and
Mg2+ (at concentrations between 1 and 10 mM) have been
shown to block the antimicrobial activity of many of these
proteins, including BPI, azurocidin, cathepsin G, and defen-
sins (12, 35, 37, 42, 53). The divalent cation concentrations
within the neutrophil phagolysosome have not been defined.
However, it is reasonable to hypothesize that for the neu-
trophil proteins to function, the cation concentrations are
likely to be comparable to those within the macrophage.
Thus, this may be another site where lactoferrin and lacto-
ferricin could be active. Quite recently, defensin-like pep-
tides have been isolated from both tracheal tissue (tracheal
antimicrobial peptide) and murine small intestine Paneth
cells (cryptdins) (14, 15). This result would suggest that there
are other in vivo microenvironments where antimicrobial
peptides are active.
In spite of the similarities in activity noted above, there
are also clear differences between the antimicrobial effects of
the whole lactoferrin molecule and its peptide fragment,
lactoferricin. While under appropriate conditions they re-
lease comparable amounts of tritiated LPS, under these
conditions the whole protein is bacteriostatic and the peptide
is bactericidal. Moreover, while iron saturation completely
blocks the effect of whole lactoferrin, higher iron concentra-
tions are required to partially block the activity of lactoferri-
cin. However, these observations remain consistent with the
general hypothesis that the outer membrane effects of the
molecules are mediated by a polycationic mechanism of
action. Work by Lehrer and associates (33) suggests that the
bactericidal activity of defensins toward E. coli relates to an
ability to disrupt the inner and outer membrane of this
bacteria and that cell death is coincident with inner mem-
brane permeabilization. There is a major size difference
between the whole lactoferfin molecule (-83,000 Da) and
free lactoferricin (3,126 Da) (5, 43). It is reasonable to
hypothesize that the peptide fragnent might be able to
penetrate through the outer membrane to reach and damage
the inner membrane and kill the cell. In contrast, because of
its size the whole lactoferrin protein may be sterically
blocked and able to damage only the outer membrane.
Similarly, when lactoferrin becomes iron saturated, there are
changes in both the three-dimensional structure of the mol-
ecule and its molecular flexibility (4). Thus, while the amino-
terminal domain of lactoferrin is not associated with the
chelating activity of the molecule, the decrease in overall
molecular flexibility associated with iron chelation may
decrease the ability of the protein to interact with the
bacterial cell. It is also possible that ferric iron could
interfere with the activity of lactoferrin and lactoferricin in a
manner similar to the divalent cations. Such an effect is
particularly likely in relation to the effect of iron on lacto-
ferricin, which is distinct from the iron-binding domain of
whole lactoferrin and should therefore not be influenced by
conformational changes related to chelation. Each of these
hypotheses will need experimental confirmation.
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